Comparison of Scalp Microbiota of the Psoriasis and Seborrheic Dermatitis Patients

Comparison of Scalp Microbiota of the Patients With Psoriasis Vulgaris and Seborrheic Dermatitis

A sterile swap specimen taken from the scalp of the patients with psoriasis vulgaris or seborrheic dermatitis and the volunteer control group will be examined in our study. The examples of the microbiota of the patients will be taken both the lesional scalp and the lesion-free part of the scalp. Then, the microbiota differences between the lesioned scalp and the lesion-free scalp of both groups, and the microbiome differences between the two groups and the control group will be evaluated.

Study Overview

• Status: Completed
• Conditions: Microbial Colonization; Seborrheic Dermatitis; Psoriasis Vulgaris
• Intervention / Treatment: Other: Microbiota

• Study Type: Observational
• Enrollment (Actual): 30

Contacts and Locations

Study Locations

• Turkey
  • Istanbul, Turkey
    • Melek Aslan Kayıran

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

primary care clinic and community sample

Description

Inclusion Criteria:

1. Patients with scalp psoriasis
2. Patients with seborrheic dermatitis
3. Agree to participate in research 4 - Do not use any drugs for their disease topically or systemically for two months

Exclusion Criteria:

1. Patients who do not want to participate in the study
2. Patients with psoriasis vulgaris or seborrheic dermatitis that does not effect scalp.
3. Those with chronic diseases that may affect skin microbiome
4. Patients using antibiotics, antifungal or antiviral therapy for any reason for the last one month.
5. Patients who are using topical or systemic drugs for their illness

Study Plan

How is the study designed?

Number of groups / cohorts

5

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Control Group	Other: Microbiota; The scalp microbiota
Psoriasis Vulgaris patients-Lesion	Other: Microbiota; The scalp microbiota
Psoriasis Vulgaris patients-Lesion free	Other: Microbiota; The scalp microbiota
Seborrheic Dermatitis-Lesion	Other: Microbiota; The scalp microbiota
Seborrheic Dermatitis-Lesion free	Other: Microbiota; The scalp microbiota

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The scalp microbiota of the patients with psoriasis and seborrheic dermatitis	The aim of this study is to compare the scalp microbiota of psoriasis vulgaris and seborrheic dermatitis both the lesion and lesion-free parts and also the control group and to assess their role on etiopathogenesis. Determining the microbiota of this region which is frequently involved and resistant to treatment may change the treatment approach. In addition, scalp microbiome of seborrheic dermatitis may be a causal factor of rapid relapse after treatment. The similarities between the microbiota of the psoriasis vulgaris and seborrheic dermatitis cases with only scalp involvement can guide us not only for the diagnosis but also the treatment. There are a few reports about the role of Malassezia subgroups in the pathogenesis, but it is known that there are many different flora members on the scalp. Exposing these can change both our diagnosis and treatment options.	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The differences between the scalp microbiota of different countries	Does the microbiota of the patients change between the countries? To our knowledge, there is no similar studies in present. Presenting the scalp microbiome of Turkish population can be a start to understand whether there is a difference in terms of the countries.	6 months

Collaborators and Investigators

• Sponsor: Istanbul Medeniyet University
• Collaborators: Turkish Dermatology Association

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 25, 2019
• Primary Completion (ACTUAL): June 18, 2019
• Study Completion (ACTUAL): June 18, 2019

Study Registration Dates

• First Submitted: January 5, 2019
• First Submitted That Met QC Criteria: January 14, 2019
• First Posted (ACTUAL): January 17, 2019

Study Record Updates

• Last Update Posted (ACTUAL): September 10, 2020
• Last Update Submitted That Met QC Criteria: September 8, 2020
• Last Verified: September 1, 2020

More Information

Terms related to this study

• Keywords: Microbiome; Scalp; Psoriasis Vulgaris; Seborrheic Dermatitis
• Additional Relevant MeSH Terms: Pathologic Processes; Skin Diseases; Disease Attributes; Skin Diseases, Papulosquamous; Skin Diseases, Eczematous; Sebaceous Gland Diseases; Infections; Communicable Diseases; Psoriasis; Dermatitis; Dermatitis, Seborrheic
• Other Study ID Numbers: IstanbulMU2

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No